Fc-Engineered Anti-ICOS Antibodies for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-ICOS antibodies fail to effectively stimulate effector T cell responses and deplete regulatory T cells, limiting their therapeutic efficacy in cancer treatment, particularly when combined with immune-checkpoint inhibitors.
Innovation Solution
Development of novel antibodies that differentially target human ICOS, combining agonistic activity to stimulate effector T cells and Fc-mediated depletion of regulatory T cells, optimizing the balance between these cell types to enhance anti-tumor responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-ICOS antibodies are used to target ICOS, then ICOS binding is achieved, but effector T cell stimulation and regulatory T cell depletion are insufficient
Solution Approach 1:
The patent applies local quality by engineering the antibody to have different functional properties at different regions: the variable region binds to ICOS with high affinity while the Fc region is engineered to mediate selective depletion of regulatory T cells. This regional differentiation allows the same antibody molecule to simultaneously stimulate effector T cells through ICOS binding while depleting suppressive regulatory T cells through Fc-mediated mechanisms, thereby resolving the contradiction between reliable ICOS targeting and sufficient T cell response productivity.
Solution Approach 2:
The patent employs parameter changes by modifying the Fc region of the antibody to alter its effector function parameters. Specifically, the Fc region is engineered to enhance ADCC (antibody-dependent cellular cytotoxicity) and ADCP (antibody-dependent cellular phagocytosis) activities, which enables selective depletion of regulatory T cells. This parameter modification transforms the antibody from a simple binding agent into a dual-function molecule that both binds ICOS reliably and actively depletes regulatory T cells, thereby improving therapeutic efficacy without compromising T cell response stimulation.
2Reliability
If anti-ICOS antibodies are used in combination with immune-checkpoint inhibitors, then cancer treatment is enhanced, but therapeutic efficacy is limited without adequate effector T cell stimulation
Solution Approach 1:
The patent applies merging by combining multiple functions into a single antibody molecule: ICOS binding capability, effector T cell stimulation through ICOS activation, and regulatory T cell depletion through Fc-mediated ADCC/ADCP. This merged antibody can be administered as a single agent or in combination with immune-checkpoint inhibitors, simplifying the treatment regimen while maintaining enhanced anti-tumor efficacy. The combination approach allows the antibody to work synergistically with immune-checkpoint inhibitors, improving ease of operation without compromising reliability.
Solution Approach 2:
The patent implements universality by designing an antibody with multi-functional capabilities that can operate in multiple contexts: it binds ICOS on various T cell subsets, stimulates effector T cells, depletes regulatory T cells, and works in combination with different immune-checkpoint inhibitors. This universal design allows the antibody to be broadly applicable in cancer immunotherapy settings, enhancing ease of operation by providing a versatile tool that addresses multiple therapeutic needs simultaneously while maintaining reliable anti-tumor effectiveness.
3Productivity
If regulatory T cells are not depleted, then immune suppression persists, but effector T cell activation alone is insufficient for tumor control
Solution Approach 1:
The patent applies the blessing in disguise principle by converting the harmful suppressive function of regulatory T cells into a beneficial therapeutic effect. The engineered antibody specifically targets and depletes regulatory T cells through Fc-mediated ADCC and ADCP mechanisms, transforming the previously harmful immune suppression into a benefit by removing the suppressive barrier. This allows the simultaneously activated effector T cells to function effectively against tumors, thereby increasing anti-tumor immune response productivity while eliminating regulatory T cell harmful factors.
Solution Approach 2:
The patent implements preliminary anti-action by preemptively depleting regulatory T cells before they can suppress effector T cell function. The antibody's Fc-mediated depletion mechanism acts in advance to remove the suppressive population, creating a favorable immune environment for subsequent effector T cell activation and tumor attack. This preliminary removal of harmful regulatory T cells ensures that when effector T cells are stimulated, they encounter minimal suppression, thereby maximizing anti-tumor immune response productivity while countering harmful factors early in the therapeutic process.
Data Source
AI summary
Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Combinations of anti-ICOS antibodies and other drugs for immunooncology.